Sources growth-equity opportunities for technology and healthcare companies across North America, combining deal origination with hands-on operational support to accelerate scale. Joel Top leverages prior operating roles and investor networks to underwrite revenue-driven business models and lead board-level execution. Background includes product and commercial leadership, with experience deploying capital across Series A–C rounds; education includes business school and engineering roots.
Sources growth-equity opportunities for technology and healthcare companies across North America, combining deal origination with hands-on operational support to accelerate scale. Joel Top leverages prior operating roles and investor networks to underwrite revenue-driven business models and lead board-level execution. Background includes product and commercial leadership, with experience deploying capital across Series A–C rounds; education includes business school and engineering roots.
Focuses on growth-equity investments in North American technology and healthcare companies, prioritizing revenue-driven models with clear unit economics and repeatable go-to-market engines. Combines rigorous commercial underwriting with hands-on operational support and board-level leadership to accelerate scale, de-risk execution, and structure follow-on capital. Targets Series A–C opportunities with a 3–7 year horizon, emphasizing measurable growth KPIs, disciplined capital allocation, and an operator-led playbook to optimize product and commercialization.
Focuses on growth-equity investments in North American technology and healthcare companies, prioritizing revenue-driven models with clear unit economics and repeatable go-to-market engines. Combines rigorous commercial underwriting with hands-on operational support and board-level leadership to accelerate scale, de-risk execution, and structure follow-on capital. Targets Series A–C opportunities with a 3–7 year horizon, emphasizing measurable growth KPIs, disciplined capital allocation, and an operator-led playbook to optimize product and commercialization.
| Trades 237 | Longs Won 131/237 55% | Profit Factor 22.22 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $294,380.71 |
| Average Win $193,564.01 | Best Trade (Jul 14) $2.17M | Sharpe Ratio -126.8 |
| Average Loss -$10,764.03 | Worst Trade (Mar 31) -$397,674.76 | Z-Score -8.65 (100%) |
| Commissions $0 | Avg. Trade Length 4m 3w 1d | Expectancy $102,176.79 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 13,333 | 12,000 | 10,667 | 9,333 | 8,000 | 6,667 | 5,333 | 4,000 | 2,667 | 1,333 |